Pharmaceutical company Avenacy has launched Propofol injectable emulsion, USP, in the U.S. to be used for intravenous general anesthetic and sedation.
The drug has been approved by the FDA as a generic equivalent to general anesthetic Diprivan, according to an April 7 press release.
It is approved for use for induction of general anesthesia in patients over age 3, maintain anesthesia for patients over 2 months old, maintain monitored anesthesia care, sedate patients in combination with regional anesthesia and for intubation of mechanically ventilated patients.
This is Avenacy’s 21st product launch since October 2023.
The post FDA approves new general anesthetic appeared first on Becker’s ASC.
